Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team will engage in an in-person fireside chat on September 5, 2024, at 5:35 pm EDT (21:35 GMT).
Investors and interested parties can access a live audio webcast of the fireside chat through Alvotech's investor website in the events section. For those unable to attend live, a recording will be archived and available for at least 90 days after the event, providing an opportunity to gain insights into Alvotech's strategies and developments in the biosimilar market.
Alvotech (NASDAQ: ALVO), una società biotecnologica globale focalizzata su medicinali biosimilari, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley a New York. Il team di gestione dell'azienda parteciperà a un incontro informale di persona il 5 settembre 2024, alle 17:35 EDT (21:35 GMT).
Gli investitori e le parti interessate possono accedere a un webcast audio dal vivo dell'incontro attraverso il sito web per investitori di Alvotech nella sezione eventi. Per coloro che non possono partecipare in diretta, una registrazione sarà archiviata e disponibile per almeno 90 giorni dopo l'evento, offrendo un'opportunità di comprendere le strategie di Alvotech e gli sviluppi nel mercato dei biosimilari.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global centrada en medicamentos biosimilares, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York. El equipo directivo de la compañía participará en un charla informal en persona el 5 de septiembre de 2024, a las 5:35 p. m. EDT (21:35 GMT).
Los inversores y partes interesadas pueden acceder a un webcast de audio en vivo de la charla a través del sitio web de inversores de Alvotech en la sección de eventos. Para aquellos que no puedan asistir en vivo, se archivará una grabación y estará disponible durante al menos 90 días después del evento, brindando la oportunidad de obtener información sobre las estrategias y desarrollos de Alvotech en el mercado de biosimilares.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품에 중점을 둔 글로벌 생명공학 기업으로 뉴욕에서 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사의 경영진은 2024년 9월 5일 오후 5시 35분 EDT (GMT 21:35) 에서 대면 화상 대담에 참여할 예정입니다.
투자자와 관심 있는 분들은 Alvotech의 투자자 웹사이트의 이벤트 섹션을 통해 대담의 실시간 오디오 웹캐스트에 접근할 수 있습니다. 실시간으로 참석하지 못하는 분들을 위해서는 녹음이 보관될 예정이며 이벤트 이후 최소 90일간 이용 가능하여, Alvotech의 전략 및 바이오시밀러 시장의 발전에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Alvotech (NASDAQ: ALVO), une entreprise biotechnologique mondiale spécialisée dans les médicaments biosimilaires, a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley à New York. L'équipe de direction de l'entreprise participera à une discussion informelle en personne le 5 septembre 2024 à 17h35 EDT (21h35 GMT).
Les investisseurs et les personnes intéressées peuvent accéder à un webinaire audio en direct de la discussion via le site Web des investisseurs d'Alvotech dans la section des événements. Pour ceux qui ne peuvent pas assister en direct, un enregistrement sera archivé et disponible pendant au moins 90 jours après l'événement, offrant une occasion de comprendre les stratégies et les développements d'Alvotech sur le marché des biosimilaires.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich auf Biosimilarmedikamente konzentriert, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley in New York angekündigt. Das Management-Team des Unternehmens wird am 5. September 2024 um 17:35 Uhr EDT (21:35 GMT) an einem persönlichen Gespräch teilnehmen.
Investoren und interessierte Parteien können über die Investorenseite von Alvotech im Bereich Veranstaltungen auf ein live-Audio-Webcast des Gesprächs zugreifen. Für diejenigen, die nicht live teilnehmen können, wird eine Aufzeichnung archiviert und mindestens 90 Tage nach der Veranstaltung verfügbar sein, was die Möglichkeit bietet, Einblicke in die Strategien und Entwicklungen von Alvotech auf dem Biosimilar-Markt zu gewinnen.
- None.
- None.
REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Members of the management team will hold an in-person fireside chat on September 5, 2024, starting at 5:35 pm EDT (21:35 GMT).
A live audio webcast of the fireside chat will be available and can be accessed either during or after the event in the events section on Alvotech’s investor website. A recording will also be archived and available for at least 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
When is Alvotech (ALVO) participating in the Morgan Stanley Healthcare Conference?
How can investors access Alvotech's (ALVO) fireside chat at the Morgan Stanley conference?
What is the focus of Alvotech's (ALVO) business?
Where is the Morgan Stanley Healthcare Conference that Alvotech (ALVO) is attending taking place?
